ArticleScientific reports2019
Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Understanding Ultrasound Features that Predict Symptom Severity in Patients with Adenomyosis: a Systematic Review.Reproductive sciences (Thousand Oaks, Calif.) · 2024Pooled it
- Treatment selection for adenomyosis based on imaging findings and patient characteristics.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
- Pretreatment MRI parameters as predictive biomarkers for short-term clinical response to dienogest in adenomyosis: a retrospective cohort study.Abdominal radiology (New York) · 2026Article
- Phenotypic heterogeneity in adenomyosis: internal and external subtypes.Archives of gynecology and obstetrics · 2025Observational
- Prognostic factors of progesterone resistance in symptomatic adenomyosis: impact of lesion localization on treatment outcome of levonorgestrel intrauterine system.BMC women's health · 2025Article
- Risk factors and countermeasures for abnormal uterine bleeding during dienogest therapy for adenomyosis: a review.Frontiers in reproductive health · 2025Review
- Association of hemorrhagic shock and pulmonary embolism following the administration of dienogest in a patient diagnosed with adenomyosis.Radiology case reports · 2024Article
- Adenomyosis-A Call for Awareness, Early Detection, and Effective Treatment Strategies: A Narrative Review.Healthcare (Basel, Switzerland) · 2024Review
- Impact of Adenomyosis on Infertile Patients-Therapy Options and Reproductive Outcomes.Biomedicines · 2022Review
- Treatment of endometriosis with dienogest in combination with traditional Chinese medicine: A systematic review and meta-analysis.Frontiers in surgery · 2022Review
- Conservative Management of Uterine Adenomyosis: Medical vs. Surgical Approach.Journal of clinical medicine · 2021Review
- A controlled clinical trial comparing potent progestins, LNG-IUS and dienogest, for the treatment of women with adenomyosis.Reproductive medicine and biology · 2021Article
- Clinicopathological characteristics and imaging findings to identify adenomyosis-related symptoms.Reproductive medicine and biology · 2021Article
- The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosis.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to retrospectively analyze the risk factors of a continuous dienogest (DNG) therapy for serious unpredictable bleeding in patients with symptomatic adenomyosis. This is a retrospective study based on data extracted from medical records of 84 women treated with 2 mg of DNG orally each day between 2008 and 2017. 47 subjects were excluded from the original analyses due to an inadequate subcategorization into subtype I and subtype II and a lack of hemoglobin levels. The influence of various independent variables on serious unpredictable bleeding was assessed. Of the 37 eligible patients who received the continuous DNG therapy, 14 patients experienced serious unpredictable bleeding. Univariate analysis revealed that the serious bleeding group had subtype I adenomyosis (P = 0.027). There was no correlation between age, parity, minimum hemoglobin level before treatment, previous endometrial curettage, and duration of DNG administration, or uterine or adenomyosis size and the serious bleeding. A DNG-related serious unpredictable bleeding is associated with the structural type of adenomyosis (subtype I) in patients with symptomatic adenomyosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.